KDR and neoplasm: Cabozantinib (XL184) is a tyrosine kinase inhibitor of the c-MET and RET kinase pathway as well as the vascular endothelial growth factor receptor 2 (VEGFR2) which impairs tumor cell proliferation and angiogenesis [12–16].